The Anesthesiologists' Perception of Malignant Hyperthermia and Availability of Dantrolene in China: A Cross-Sectional Survey
DOI: https://doi.org/10.2147/rmhp.s454895
2024-03-29
Risk Management and Healthcare Policy
Abstract:Jiechu Wang, 1– 3, &ast Yao Yu, 1, &ast Ya Gao, 1– 3, &ast Tingting Wan, 1– 3 Zhukai Cong, 1– 3 Zhengqian Li, 1– 3 Yang Zhou, 1– 3 Xiaoxiao Wang, 4 Luyang Feng, 1– 3 Yongzheng Han, 1– 3 Jing Zhang, 1– 3 Yinyin Qu, 1– 3 Xiangyang Guo 1– 3 1 Department of Anesthesiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 2 Beijing Center of Quality Control and Improvement on Clinical Anesthesia, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 3 Anesthesia and Perioperative Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Beijing, 100191, People's Republic of China; 4 Research Center for Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiangyang Guo; Yinyin Qu, Department of Anesthesiology, Peking University Third Hospital, North Garden Road 49, Haidian District, Beijing, 100191, People's Republic of China, Email ; Background: Malignant hyperthermia (MH) is a hypermetabolic syndrome with high mortality rates. Early detection and prompt intravenous administration of dantrolene are crucial for effective management of MH. However, there is currently a lack of comprehensive nationwide surveys on the availability of dantrolene and anesthesiologists' understanding of MH in China. Methods: A nationwide survey was conducted between January 2022 and June 2022. Online questionnaires on the cognition of MH among anesthesiologists in China were sent through social platforms to anesthesiologists in mainland China. Data regarding participants' perception of MH-related knowledge, availability of domestic dantrolene, and reported MH cases were collected in this study. Results: Responses were collected from a total of 11,354 anesthesiologists representing 31 provinces across the Chinese mainland. Among the 11 scoring questions, the highest accuracy rates were observed for the question regarding therapeutic drugs for MH (99.3%) and the characteristics of MH (98.0%). Conversely, the question pertaining to the earliest clinical signs of MH had the lowest accuracy rate (23.5%). Significant variations were observed in the scores among different professional titles ( P =0.003), academic degree ( P < 0.001), hospital classification ( P < 0.001), and urban hierarchy ( P < 0.001). Of the respondents, 919 (8.1%) anesthesiologists reported dantrolene availability in their hospitals, and 631 (5.6%) indicated unclear. A total of 136 hospitals in this survey reported at least one previous case of MH. Conclusion: Mainland China faces challenges such as insufficient experience in diagnosing and treating MH, as well as difficulty in obtaining dantrolene. To improve the public awareness of MH, it is imperative to establish and promote a refined MH training system. Additionally, a streamlined and rapid dantrolene linkage emergency system should be implemented to ensure prompt access to the drug. Keywords: malignant hyperthermia, dantrolene, China, anesthesiologists, survey Malignant hyperthermia (MH) is a hypermetabolic syndrome mainly inherited in autosomal dominant way. It often occurs after exposure to volatile anesthetics and/or depolarized muscle relaxant succinylcholine, and rarely by stress and heat. The estimated incidence of MH varies between 1/10,000 and 1/250,000 anesthetic procedures. 1–3 With an increasing understanding of MH and introduction of intravenous dantrolene in 1979, the mortality rates has decreased from 80.0% to 1.4% in developed countries. 4 The mortality rates associated with MH in China was reported as high as 73.5% in the early 21 st century. 5 A retrospective analysis of the suspected MH patients from 2015 to 2020 reported a mortality rate of 53.4%. 6 Lack of awareness concerning the availability and accessibility of the orphan drug dantrolene was considered to attribute to the high mortality rates with MH. Intravenous dantrolene was not available in mainland China until Oct 2020, however, the current reserve of domestic dantrolene is not clear. Lack of awareness among anesthesiologists and patients makes it difficult to identify susceptible individuals before the surgery, detect early signs of MH, and provide prompt treatment. To solve these problems, the expert consensus on the prevention and treatment of MH was published by the Chinese Society of Anesthesiologists (CSA) in 2018 and upda -Abstract Truncated-
health care sciences & services,health policy & services